Rekah Pharmaceutical Industry Ltd. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was ILS 66.85 million compared to ILS 63.1 million a year ago. Net loss was ILS 0.517 million compared to net income of ILS 1.36 million a year ago. Basic loss per share from continuing operations was ILS 0.05 compared to basic earnings per share from continuing operations of ILS 0.12 a year ago. Diluted loss per share from continuing operations was ILS 0.05.
For the six months, sales was ILS 139.31 million compared to ILS 127.78 million a year ago. Net income was ILS 0.022 million compared to ILS 3.25 million a year ago.